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85 Expression of Unfolded Protein Response (UPR) protein
markers are increased in primary and cystic ﬁbrosis (CF) nasal
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NP is a useful model to study pathogenesis of chronic airway inﬂammation.
NP could be either of unknown origin (primary NP) or secondary to congenital
impairment of mucociliary clearance (CF, or primary ciliary dyskinesia, PCD).
The aim of the present study was to identify the differentially expressed proteins
using human nasal epithelial cell (HNEC) primary cultures from NP, and two
successive proteomic approaches (2D gels following mass spectrometry (MS) and
semi-quantitative iTRAQ MS/MS analysis). Using 2D approach, 51 proteins were
identiﬁed (pH range 5−8) with 7 being differentially expressed between primary NP
(n = 4) and secondary NP (2 CF, 2 PCD). Using iTRAQ approach, 583 proteins were
identiﬁed with 21 and 25 of them being differentially expressed between primary
NP (n = 1) vs control mucosa (n = 1) and primary NP (n = 1) vs CF NP (n = 1),
respectively. These proteins include inﬂammatory (annexin 1 and 2), oxidative
stress (peroxiredoxin 1, GSTp1), structural (keratin 18, alpha actinin) and chaperone
proteins (several HSPs). Multiple proteins belonging to Unfolding Protein Response
(UPR) proteins (e.g. PPIB, HSP70, GRP78) were also identiﬁed. Focusing on the
UPR, we found that UPR decreases as function of time in HNEC cultures from
p_NP (n = 3). Cytokine secretion, measured in same HNEC, decreases in parallel
to UPR response (n = 3). All together, these results suggest that UPR is related to
inﬂammatory microenvironment and play a role in pathogenesis of primary and CF
NP.
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The evaluation of functional CFTR to assess new therapies and deﬁne diagnosis
of atypical cases in cystic ﬁbrosis (CF) is cumbersome and practicable only for
selected subjects in few centers. It is known that leucocytes express detectable
levels of CFTR.
We investigated the possibility to assess CFTR activity in leucocytes obtained from
healthy subjects or patients with cystic ﬁbrosis ex vivo.
We measured higher levels of CFTR expression in monocytes and lymphocytes than
in polymorphonuclear cells by immune-precipitation and ﬂow cytometric assays.
To determine CFTR activity in monocytes isolated from non-CF donors (non-
CF), heterozygous subjects (HTZ) and CF patients we measured cell membrane
depolarization, by single-cell ﬂuorescence imaging, using the potential-sensitive
probe bis-(1,3-diethylthiobarbituric acid) trimethine oxonol (DiSBAC2(3)). We
found that, upon stimulation, only non-CF and, to a lesser extent, HTZ monocytes
showed an increase in ﬂuorescence signal while monocytes from CF patients failed
to respond. In comparison, we measured nasal potential differences in selected
subjects obtaining overlapping results.
Our ﬁndings promote the evaluation of CFTR activity in monocytes by optical
techniques as a useful tool to assess CFTR activity for basic and translational
research, including drug development, and diagnostic applications.
C. Sorio and M. Buffelli equally contributed to this work.
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The human cathelicidin antimicrobial peptide acts as effector molecule of the
pulmonary innate immune system with direct antimicrobial and immunomodulatory
effects. The aim of this study was to test whether the cathelicidin LL-37 modulates
the response of neutrophils to microbial stimulation. Human neutrophils exposed
to LPS, Staphylococcus aureus and Pseudomonas aeruginosa following incubation
with LL-37. Cytokine production was measured by ELISA and the incubation with
LL-37 signiﬁcantly decreased the release of proinﬂammatory cytokines from human
neutrophils stimulated with TLR ligands or whole bacteria. ROS production of
neutrophils was determined by a luminometeric and a ﬂow cytometry method.
The peptide induced the production of ROS and the engulfment of bacteria
into neutrophils. Peritoneal mouse neutrophils isolated from CRAMP deﬁcient
and wildtype animals were treated with LPS and TNF-alpha in the supernatant
was measured by ELISA. Antimicrobial activity of neutrophils was detected by
incubating neutrophils isolated from CRAMP knockout and wildtype mice with
bacteria. Neutrophils from CRAMP deﬁcient mice released signiﬁcantly more
TNF-alpha after LPS stimulation and showed decreased antimicrobial activity as
compared to cells from wildtype animals. In conclusion, LL-37 modulates the
response of neutrophils to bacterial activation. Cathelicidin controls the release of
inﬂammatory mediators while increasing antimicrobial activity of neutrophils. This
mechanism could be useful in the development of novel antiinfectious treatments
for CF lung disease.
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In addition to its use in CF diagnosis, the nasal potential difference (NPD) provides
useful information about airway physiology in vivo. We have previously shown
that topical hypertonic saline, but not mannitol, alters NPD in non-CF subjects
Eur Respir J 2001: 17: 195–199). This abstract compares the effects of different
hypertonic solutions on NPD in CF and non-CF subjects.
Methods: Topical application of (i) sodium chloride (500mM), (ii) sodium glu-
conate (500mM), (iii) NMDG-chloride (500mM), (iv) mannitol (1M) were tested
in CF and non-CF subjects (n = 6), on separate days, with and without amiloride
pre-treatment.
Results: In non-CF subjects hypertonic solutions of sodium chloride and NMDG-
chloride signiﬁcantly decreased the nasal PD, but no decrease was seen with man-
nitol and sodium gluconate. However, following amiloride pre-treatment, mannitol
signiﬁcantly increased PD, suggesting that hypertonicity can induce changes in
multiple ion transport pathways. In contrast, CF subjects showed much larger
reductions in PD with sodium chloride and NMDG-chloride. Mannitol and sodium
gluconate signiﬁcantly decreased PD via amiloride sensitive mechanisms.
Conclusion: In the non-CF airway, hypertonic solutions containing chloride
markedly reduce nasal PD via amiloride sensitive pathways. These responses are
enhanced in CF subjects. Mannitol appears to have two effects – an amiloride
sensitive decrease in PD, matched by a CFTR-related increase in PD. These complex
results suggest that the CF-related ion transport defects are involved in the airway
responses to hypertonic solutions. This may have important therapeutic ramiﬁcations
for the treatment of CF lung disease.
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